Medicines & Healthcare products Regulatory Agency

MHRA
Regulating Medicines and Medical Devices

ANNEX 1
Response document for MHRA public consultation on the proposal to make Acnecide Face Gel and Acnecide Face Wash available from general sales outlets without prescription

Ref: ARM 98

Your details
Name: [redacted]

Position (if applicable): Retired

Organisation (if applicable): N/A

Email: [redacted]@[redacted]

1. **Do you consider that Acnecide Face Gel and Acnecide Face Wash should be available as General Sale List (GSL) medicines?**

Yes ☑ No ☐ Not sure ☐

Please provide any comments or evidence to support your response: My daughter has used Acnecide face gel for over 6 years. It is the only thing that has ever worked for her skin as before she was using Freederm gel that only made her skin worse. She uses it for the odd outbreak on her cheeks and hasn't had any problems or side affects from using it. It would be helpful for her to get it from regular shops as we don't have a lot of pharmacies where we are and she has to travel a long way to buy it which is very inconvenient.

2. **Do you have any specific comments on the leaflets or the labels provided in the public reclassification report for Acnecide Face Gel and Acnecide Face Wash?**

All info in the instructions seem correct

3. **Do you have any other comments on the reclassification?**

My daughter has tried dozens of different spot treatments and none had worked until she found Acnecide face gel. It has really helped to get her skin clear and healthy and has given her self-esteem a big boost. It is a great product and should be more widely available

4. The MHRA may publish consultation responses. Do you want your response to remain confidential?

Yes ☐ Partially* ☐ No ☑

*If partially, please indicate which parts you wish to remain confidential. In line with the Freedom of Information Act 2000, if we receive a request for disclosure of the information, we will take full account of your explanation, but we cannot give an assurance that confidentiality can be maintained in all circumstances. Responses to consultation will not normally be released under FOI until the regulatory process is complete.

Responses can be continued onto a separate page if required. This form should be returned by email (reclassification@mhra.gov.uk) to arrive by **30 May 2019.** Contributions received after that date cannot be included in the exercise.